Evidence map›Paper›PMID 42730031›Full record

ArticleRSC chemical biology2026

PrismaLuc luciferase enables tunable near-infrared bioluminescence for

Felipe Gama-Franceschi, Rachel Friedman Ohana, Chao Gao, Thomas Kirkland, Laura Mezzanotte

Abstract read
In one paragraph

Article in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Felipe Gama-FranceschiDepartment of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Centre Rotterdam The Netherlands.ORCID https://orcid.org/0000-0001-5393-7305
Rachel Friedman OhanaPromega Corporation Madison Wisconsin USA.ORCID https://orcid.org/0000-0001-6706-4592
Chao GaoPromega Corporation Madison Wisconsin USA.ORCID https://orcid.org/0000-0003-3662-6518
Thomas KirklandPromega Corporation Madison Wisconsin USA.ORCID https://orcid.org/0000-0003-0859-5785
Laura MezzanotteDepartment of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Centre Rotterdam The Netherlands.ORCID https://orcid.org/0000-0001-5592-8904

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioluminescence imaging (BLI) enables non-invasive monitoring of biological processes in living animals, yet most bioluminescent reporters emit at fixed wavelengths with limited spectral flexibility, constraining their use in multiplexed and deep-tissue applications. Bioluminescence resonance energy transfer (BRET) offers a solution by coupling a luciferase to a proximal fluorescent protein or synthetic fluorophore that absorbs the emitted light and re-emits it at a longer wavelength. However, existing BRET systems built from luciferase-fluorescent protein fusions are limited by suboptimal energy transfer efficiency and the fixed photophysical properties of their genetically encoded chromophores. We recently introduced PrismaLuc, a high-efficiency BRET reporter, in which a circularly permuted NanoLuc is inserted into HaloTag, enabling efficient energy transfer to a covalently bound synthetic fluorophore whose emission wavelength is selected by choice of ligand. In our initial report, PrismaLuc was paired with JF549 HaloTag ligand for two-colour cell-based assays. Here, we extend PrismaLuc to

Identifiers

PMID42730031
PMCPMC13565418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.